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Objectives: The aim of the present study was to
assess the appropriate administration dose of non-
steroidal anti-inflammation drugs to prevent
pancreatitis after endoscopic retrograde
cholangiopancreatography (ERCP). Importantly, the
100 mg dose of diclofenac recommended in Western
countries has not been permitted in Japan.
Design: A retrospective study.
Settings: A single centre in Japan.
Participants: This study enrolled patients who
underwent ERCP at the Department of
Gastroenterology, Osaka Saiseikai Senri Hospital, from
April 2011 through June 2013, and who received either
a 25 or a 50 mg dose of rectal diclofenac after ERCP.
Primary outcome measure: The occurrence of post-
ERCP pancreatitis (PEP). A multivariate regression
model was used to assess the effect of the 50 mg dose
(the 50 mg group) of rectal diclofenac and to compare it
to the occurrence of PEP referring to the 25 mg group.
Results: A total of 155 eligible patients received either
25 mg (84 patients) or 50 mg (71 patients) doses of
rectal diclofenac after ERCP to prevent PEP. The
proportion of PEP was significantly lower in the 50 mg
group than in the 25 mg group (15.5% (11/71) vs
33.3% (28/84), p=0.018). In a multivariate analysis, the
occurrence of PEP was significantly lower in the 50 mg
group than in the 25 mg group even after adjusting
potential confounding factors (adjusted OR=0.27, 95%
CI 0.11 to 0.70).
Conclusions: From this observation, the occurrence of
PEP was significantly lower among ERCP patients with
the 50 mg dose of rectal diclofenac than among those
with the 25 mg dose.
INTRODUCTION
Endoscopic retrograde cholangiopancreato-
graphy (ERCP) is widely conducted as a
therapeutic and diagnostic procedure for
hepatobiliary-pancreatic diseases.1–6 However,
the prevalence of ERCP adverse events has
become high, and post-ERCP pancreatitis
(PEP) has occurred in 1–30% of patients
who have undergone ERCP. PEP can become
severe and lead to death among these
patients.1–6 Therefore, many studies on risk
factors, preventive manoeuvres and drug
administrations for PEP have been con-
ducted worldwide.1–11
Recently, numerous reports have been pub-
lished on the effectiveness of rectal adminis-
tration of non-steroidal anti-inflammation
drugs (NSAIDs) to prevent PEP.11–15 Several
randomised controlled trials revealed that
the 100 mg dose of rectal diclofenac/indo-
methacin after ERCP significantly reduced
PEP occurrence compared with non-
administration,11–15 and the rectal administra-
tion of NSAIDs after ERCP has been widely
accepted worldwide, including in Japan.16 A
meta-analysis demonstrated that NSAID
administration for PEP prevention was effect-
ive compared with non-administration, and its
effectiveness is currently being established.11
However, little is known about the appropriate
NSAID dose to prevent PEP.17 In addition, the
Strengths and limitations of this study
▪ This study showed that the occurrence of post-
endoscopic retrograde cholangiopancreatography
(ERCP) pancreatitis was significantly lower
among ERCP patients with the 50 mg dose of
rectal diclofenac than among those with the
25 mg dose.
▪ This study was a retrospective study, so there
was the potential of selection bias.
▪ This study did not assess the effect of non-ster-
oidal anti-inflammation drugs other than diclofe-
nac for prevention of post-ERCP pancreatitis.
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100 mg dose of diclofenac recommended in Western
countries has not been legally permitted in Japan.16–18
The aim of this study was to compare a 25 mg dose of
diclofenac to the 50 mg dose for the prevention of PEP
among ERCP patients. Our hypothesis is that the occur-
rence of PEP would be lower in the 50 mg group than
in the 25 mg group.
METHODS
Study design
This observation was a single-centre, retrospective study.
We enrolled patients who underwent ERCP at the
Department of Gastroenterological Medicine, Osaka
Saiseikai Senri Hospital, from April 2011 through June
2013, who then received either a 25 or 50 mg dose of
rectal diclofenac.
Settings and data collection
Osaka Saiseikai Senri Hospital, located in the northern
area of Suita City, Osaka, Japan, has 343 beds, seven
attending doctors and four residents in its Department
of Gastroenterology (50 beds). Approximately 250
patients with gastroenterological diseases annually
undergo ERCP in this hospital. The side-viewing endo-
scopes used for ERCP were either TJF-260V or JF-260V
(Olympus Corporation), and the appliance for cannula-
tion was Tandem XL TAPERED TIP and Jagwire (0.035
inch; Boston Scientific Corporation).
Among patients undergoing ERCP, either a 25 or
50 mg dose of rectal diclofenac was administered within
10 min immediately after ERCP for those more likely to
develop PEP, based on the judgment of a main ERCP
operator, and the dose (25 or 50 mg) of rectal diclofe-
nac was decided comprehensively based on patient age,
body mass index (BMI) and serum creatinine. In our
hospital, during the study period, both sulbactam
sodium/cefoperazone sodium 3.0 g/day and gabexate
mesilate 0.3 g/day were administered to all patients for
at least 2 days after ERCP, and blood tests such as serum
pancreatic-type amylase and creatinine were also con-
ducted the day after ERCP. In addition, when a doctor
in charge diagnosed or suspected PEP in a patient who
underwent ERCP, contrast-enhanced CT scanning and
blood tests were conducted.17
Information on characteristics and outcomes of ERCP
patients was retrospectively extracted from medical
records, and the following data were included: gender,
age, height, body weight, BMI, serum creatinine concen-
tration; history of hepatobiliary, pancreatic, or gastro-
intestinal cancers; history of pancreatitis, first conducted
ERCP, type of operator (resident or not), duration of
ERCP examination, difficult cannulation and ERCP indi-
vidual procedures (wire insertion into pancreatic duct,
cytology of pancreas duct, pancreatography, cytology of
bile duct), endoscopic sphincterotomy, endoscopic pap-
illary balloon dilation, choledocholithotomy and stent-
ing to pancreatic duct. Duration of ERCP examination
was defined as the time interval from the side-viewing
endoscope insertion to its removal,19 and the difficulty
of cannulation was determined by a main operator or an
attending doctor. The procedure for pancreatic duct was
defined as any one of wire insertions into the pancreatic
duct, its cytology or pancreatography.
Study end point
The primary outcome measure was the occurrence of
PEP, defined as the development of both new or wor-
sened abdominal pain and hyperamylasaemia based on
the Cotton criteria.1 6 The secondary outcome measure
was the occurrence of post-ERCP hyperamylasaemia,
defined as a rise in the serum pancreatic-type amylase
concentration to more than three times the upper limit
of the normal laboratory value (>123 IU/mL) within
24 h after ERCP.1 6 In addition, death, severe acute pan-
creatitis, acute renal failure and gastrointestinal bleeding
were defined as severe adverse events after rectal diclofe-
nac administration.1 6 Severe acute pancreatitis was
defined based on the Japanese guideline.17 Acute renal
failure was defined as an increase of the serum creatin-
ine ≥3 times over that before ERCP.20
Statistical analyses
Patient characteristics and outcomes between the two
groups with 25 and 50 mg doses of rectal diclofenac
were compared after ERCP. Continuous data were
presented as the median (interquartile), differences
were analysed by Mann-Whitney test, categorical
data were expressed in percentages (n/N) and differ-
ences were analysed by χ2 test or Fischer’s exact test.
The multivariate logistic regression was used to assess
the effect of 50 mg of rectal diclofenac (the 50 mg
group) and to compare it to the occurrence of PEP
and hyperamylasaemia referring to the 25 mg group.
The ORs and their CIs were calculated. Potential con-
founding factors based on biological plausibility and
previous studies were included in the multivariate ana-
lysis.5 6 21 These variables were gender (male, female),
age (<65, ≥65 years old), BMI (<22, ≥22 kg/m2), type
of operator (resident or not), difficult cannulation
(yes, no), and procedure in pancreatic duct (yes, no).
All statistical analyses were performed using SPSS
V.22.0J (IBM Corp, Armonk, New York). All tests were
two tailed, and p values of <0.05 were considered statis-
tically significant.
RESULTS
During the study period, a total of 166 patients received
either a 25 or 50 mg dose of rectal diclofenac after
ERCP to prevent PEP and hyperamylasaemia. Excluding
three patients who had pancreatitis and eight who were
given NSAIDs before ERCP, 155 patients (84 in the
25 mg group and 71 in the 50 mg group) were eligible
for our analysis.
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Table 1 shows the baseline characteristics and ERCP-
related procedures of eligible patients with the 25 vs
50 mg of rectal diclofenac after ERCP. The proportion
of males was significantly higher in the 50 mg group
than in the 25 mg group (64.8% vs 46.4%, p=0.022),
whereas median age was significantly lower in the 50 mg
group than in the 25 mg group (67.0% vs 73.5%,
p<0.001). The 50 mg group had significantly lower BMI
than the 25 mg group (21.9 vs 23.2, p=0.019). The pro-
portion of ERCP conducted by a resident as main oper-
ator was significantly lower in the 50 mg group than in
the 25 mg group (54.9% vs 71.4%, p=0.022). Other
factors did not differ between the groups.
Among eligible patients receiving rectal diclofenac
after ERCP, 25.2% (39/155) had PEP and 43.2%
(67/155) had post-ERCP hyperamylasaemia. The pro-
portion of PEP was significantly lower in the 50 mg
group than in the 25 mg group (15.5% (11/71) vs
33.3% (28/84), p=0.018, figure 1), and the proportion
of post-ERCP hyperamylasaemia was also significantly
lower in the 50 mg group than in the 25 mg group
(31.0% (22/71) vs 53.6% (45/84), p=0.005, figure 2).
The concentration of serum pancreatic-type amylase
after ERCP was significantly lower in the 50 mg group
than in the 25 mg group (54.0 (30.8–189.3) vs 148.0
(40.0–502.0) IU/mL, p=0.006). As for severe events after
ERCP, there were no deaths, acute renal failures or
gastrointestinal bleeding in either group, but one
patient in the 25 mg group had severe acute
pancreatitis.
In a multivariate analysis, the occurrence of PEP was
significantly lower in the 50 mg group than in the 25 mg
group even after adjusting for potential confounding
factors such as sex, age, BMI, the type of operator, diffi-
cult cannulation and procedures for pancreatic duct
(adjusted OR=0.27, 95% CI 0.11 to 0.70, table 2). The
occurrence of post-ERCP hyperamylasaemia was also sig-
nificantly lower in the 50 mg group than in the 25 mg
group (adjusted OR=0.35, 95% CI 0.15 to 0.84, table 3).
Table 1 Characteristics of patients administered a 25 versus 50 mg dose of rectal diclofenac after ERCP
Rectal diclofenac
Total 25 mg 50 mg p Value
Men, % (n/N) 54.8 (85/155) 46.4 (39/84) 64.8 (46/71) 0.022
Age (years), median (IQR) 71.0 (63.0–76.0) 73.5 (68.0–80.0) 67.0 (57.0–74.0) <0.001
Elderly aged ≥65, % (n/N) 71.0 (110/155) 82.1 (69/84) 57.7 (41/71) 0.001
BMI (kg/m2), median (IQR) 22.5 (19.5–25.3) 23.2 (21.2–25.6) 21.9 (19.2–24.4) 0.019
BMI <22 59.6 (90/151) 50.0 (40/80) 70.4 (50/71) 0.011
Cancer, % (n/N) 32.9 (50/155) 34.1 (28/82) 31.4 (22/70) 0.722
History of pancreatitis, % (n/N) 16.2 (25/154) 13.3 (11/83) 19.7 (14/71) 0.278
First conducted ERCP, % (n/N) 34.8 (54/155) 33.3 (28/84) 36.6 (26/71) 0.669
Resident as a main operator, % (n/N) 63.9 (99/155) 71.4 (60/84) 54.9 (39/71) 0.033
Serum creatinine before ERCP (mg/dL) 0.80 (0.70–0.90) 0.80 (0.70–0.90) 0.80 (0.70–1.00) 0.642
Duration of examination, median (IQR) 36.5 (26.0–51.3) 37.0 (28.0–50.0) 35.0 (23.0–53.0) 0.568
Duration of examination >30 min, % (n/N) 63.6 (98/154) 66.3 (55/83) 60.6 (43/71) 0.463
Difficult cannulation, % (n/N) 28.4 (44/155) 27.4 (23/84) 29.6 (21/71) 0.763
Procedures for pancreatic duct, % (n/N) 68.4 (106/155) 69.0 (58/84) 67.6 (48/71) 0.847
Pancreatic duct wire, % (n/N) 65.2 (101/155) 65.5 (55/84) 64.8 (46/71) 0.929
Cytology of pancreas duct, % (n/N) 19.4 (30/155) 17.9 (15/84) 21.1 (15/71) 0.608
Pancreatography, % (n/N) 31.6 (49/155) 34.5 (29/84) 28.2 (20/71) 0.397
Cytology of bile duct, % (n/N) 18.7 (29/155) 20.2 (17/84) 16.9 (12/71) 0.596
EST, % (n/N) 26.5 (41/155) 23.8 (20/84) 29.6 (21/71) 0.417
EPBD, % (n/N) 5.8 (9/155) 6.0 (5/84) 5.6 (4/71) 0.605
Choledocholithotomy, % (n/N) 38.1 (59/155) 41.7 (35/84) 33.8 (24/71) 0.315
Stenting to pancreatic duct, % (n/N) 2.6 (4/155) 2.4 (2/84) 2.8 (2/71) 0.624
BMI, body mass index; EPBD, endoscopic papillary balloon dilation; ERCP, endoscopic retrograde cholangiopancreatography; EST,
endoscopic sphincterotomy.
Figure 1 Proportion of PEP occurrence among ERCP
patients with a 25 vs 50 mg dose of rectal diclofenac
administration. ERCP, endoscopic retrograde
cholangiopancreatography; PEP, post-ERCP pancreatitis.
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From a single-centre observational study, we demon-
strated that the occurrence of PEP and post-ERCP hyper-
amylasaemia was significantly lower among ERCP
patients on the 50 mg dose of rectal diclofenac than
among those on the 25 mg dose, which suggested that
the effectiveness of diclofenac for PEP was dose depend-
ent. Importantly, the dose of diclofenac administration
for patients was limited to a single maximum of 50 mg
in Japan,16 17 but the preceding studies could not suffi-
ciently compare the effects of 25 and 50 mg doses of
rectal diclofenac for the prevention of PEP among
ERCP patients. Therefore, our study provides helpful
new clues for actual prevention of PEP at gastroentero-
logical clinical settings in Japan.
The present study showed that the prevention of PEP
among ERCP patients by diclofenac was dose-
dependently effective. Previous randomised trials and
meta-analyses indicated that 100 mg (not 50 mg) rectal
NSAID administration was more effective for PEP pre-
vention than non-administration.11–13 In a randomised
control trial in Japan, the authors showed that low doses
(either 25 or 50 mg) of rectal diclofenac were more
effective in preventing PEP compared with the placebo
group.16 From a subanalysis of the trial, the occurrence
of PEP among patients administered 50 mg of rectal diclo-
fenac tended to be lower than among those given 25 mg,
although it was statistically insignificant (0% (0/29) vs 9%
(2/22), p=0.101). This result was almost consistent with
ours. No randomised trials directly compared a 25 mg of
rectal diclofenac to a 50 mg dose for the prevention of
PEP, but conducting randomised trials to determine the
appropriate dose of NSAID administration for the pre-
vention of PEP is important in Japan.
Why does the administration of NSAIDs for ERCP
patients prevent PEP? Although much of its preventive
mechanism is unclear, it is suggested that the activation
of trypsin/trypsinogen in acinar cells of the pancreas
causes acute pancreatic inflammation by factors such as
mechanical stimulus of the pancreatic duct, intestinal
fluid flow into the pancreatic duct, increase in pancre-
atic duct internal pressure or pancreatic tissue pressure
by pancreatography and pancreatic fluid congestion by
Vater papilla oedema.11 22 23 In particular, phospholip-
ase A2 synthesised in the pancreas regulates inflamma-
tion mediators such as prostaglandins, leukotrienes and
thromboxanes by arachidonic acid cascade24 and
NSAIDs, the cyclo-oxigenase inhibitors, prevent PEP by
inhibiting its cascade.12 22–25 The efficacy of NSAIDs
including diclofenac is reportedly dose dependent.26–28
This study, showing the dose-dependent effect of diclofe-
nac for PEP prevention, suggested that sufficient doses
of NSAIDs are needed to inhibit arachidonic acid cas-
cades for PEP prevention.
Gastrointestinal bleeding and acute renal failure were
among the severe adverse events after NSAID adminis-
tration.15 Preceding studies underscored the very low
occurrence of severe adverse events such as gastrointes-
tinal bleeding and acute renal failure after NSAID
administration for PEP prevention.13 15 16 Even in the
present study, there was no gastrointestinal bleeding or
acute renal failure regardless of the dose of diclofenac,
Table 2 Association between 25 and 50 mg dose of
rectal diclofenac and post-ERCP pancreatitis
OR (95% CI) p Value
Post-ERCP pancreatitis
Univariate 0.37 (0.17 to 0.80) 0.018
Multivariate
Model 1 0.31 (0.13 to 0.75) 0.009
Model 2 0.27 (0.11 to 0.70) 0.007
ORs were calculated for the 50 mg group referring to the 25 mg
group.
Model 1: Adjusted for sex, age and BMI.
Model 2: Adjusted for sex, age, BMI, type of operator, difficult
cannulation and procedures for pancreatic duct.
BMI, body mass index; ERCP, endoscopic retrograde
cholangiopancreatography.
Figure 2 Proportion of post-endoscopic retrograde
cholangiopancreatography (ERCP) hyperamylasaemia
occurrence among ERCP patients with a 25 mg vs 50 mg
dose of rectal diclofenac administration.
Table 3 Association between 25 and 50 mg dose of
rectal diclofenac and post-ERCP hyperamylasaemia
OR (95% CI) p Value
Post-ERCP
hyperamylasaemia
Univariate 0.39 (0.20 to 0.75) 0.005
Multivariate
Model 1 0.44 (0.21 to 0.92) 0.028
Model 2 0.35 (0.15 to 0.84) 0.018
ORs were calculated for the 50 mg group referring to the 25 mg
group.
Model 1: Adjusted for sex, age and BMI.
Model 2: Adjusted for sex, age, BMI, type of operator, difficult
cannulation and procedures for pancreatic duct.
BMI, body mass index; ERCP, endoscopic retrograde
cholangiopancreatography.
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and diclofenac administration would thus be acceptable
for PEP prevention. However, gastroenterologists in
Japan tend to hesitate to use the 50 mg dose of rectal
diclofenac for PEP prevention16 17 29 because of con-
cerns such as gastrointestinal adverse events, acute renal
failure, and decrease in blood pressure after NSAID
administration.27–29 However, administering the 50 mg
dose of rectal diclofenac for patients without problems
such as renal dysfunction before ERCP should be
recommended.
NSAID administration for PEP prevention is given a
grade A recommendation by the European Society of
Gastrointestinal Endoscopy guideline, grade C1 by the
Japanese guideline, and a moderate rating by the
American College of Gastroenterology (ACG) guideline,
respectively.17 30 31 Recently, the number of patients with
acute pancreatitis has been excessively increasing,17 32
and its medical cost has also been climbing. Considering
the limited medical resources in Japan, the 50 mg dose
of rectal diclofenac for PEP prevention will surely
become an established method to be administered
without hesitation, because NSAIDs including diclofenac
are inexpensive and have few adverse effects, and their
administration method is also simple and easy. However,
large-scale prospective multicentre observational or ran-
domised trials are warranted to confirm our results.
There are several limitations to this study. First, it was
conducted retrospectively, and there was the potential of
selection bias. For example, the proportion of PEP
occurrence in this study was higher than that in previous
studies,13 16 because either a 25 or 50 mg dose of diclo-
fenac was selectively administered to ERCP patients who
were more likely to develop PEP based on the judgment
of a main ERCP operator. Second, our study did not
assess the effect of NSAIDs other than diclofenac for
PEP prevention. Third, unmeasured confounding
factors may have influenced the association between the
occurrence of PEP and rectal diclofenac administration
among ERCP patients.
CONCLUSION
From a single-centre observation in Osaka, this study
demonstrated that the occurrence of PEP and
post-ERCP hyperamylasaemia was significantly lower
among ERCP patients with the 50 mg dose of rectal
diclofenac than among those with the 25 mg dose.
Further large-scale prospective multicentre observational
or randomised controlled trials are warranted to
confirm our results.
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